Android app Apple app link

Nurix Therapeutics, Inc. (NRIX) Price Target Trimmed After Q3 Miss, Buy Rating Reaffirmed

By Yahoo! Finance   |   1 month ago
Nurix Therapeutics, Inc. (NRIX) Price Target Trimmed After Q3 Miss, Buy Rating Reaffirmed

Nurix Therapeutics (NASDAQ: NRIX), a biopharmaceutical company, reported a wider net loss in Q3 2025. Despite revenue miss and high operating expenses, the firm remains optimistic about its long-term prospects.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.